Why Glaukos Stock Zoomed Almost 14% Higher on Thursday

Core Insights - Glaukos (NYSE: GKOS) experienced a significant stock increase of nearly 14% following a strong quarterly earnings report, contrasting with a 1% decline in the S&P 500 [1] Group 1: Sales Performance - Glaukos achieved record net sales of $133.5 million in the third quarter, representing a 38% year-over-year growth, driven primarily by glaucoma treatment sales, which reached $110 million, a 45% increase compared to the same period in 2024 [2] - Analysts had anticipated third-quarter revenue to be just under $122.5 million, with a projected non-GAAP net loss of $0.26 per share, while the actual non-GAAP net loss was $9.2 million, or $0.16 per share, significantly better than the previous year's loss of over $15 million [3] Group 2: Future Guidance - Based on the current momentum, Glaukos management raised its full-year 2025 net sales guidance to a range of $490 million to $495 million, up from the previous estimate of $480 million to $486 million [4] - Preliminary guidance for full-year 2026 net sales is projected to be between $600 million and $620 million [5]